1. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy.
- Author
-
Dang, Bao-Toan Nguyen, Duwa, Ramesh, Lee, Sooyeun, Kwon, Taeg Kyu, Chang, Jae-Hoon, Jeong, Jee-Heon, and Yook, Simmyung
- Subjects
- *
CELL culture , *IMMUNOTHERAPY , *MACROPHAGES , *TOLL-like receptors , *T cells , *IMMUNOMODULATORS , *TUMOR growth - Abstract
Tumor-associated macrophages (TAMs) constitute 50–80% of stromal cells in most solid tumors with high mortality and poor prognosis. Tumor-infiltrating dendritic cells (TIDCs) and TAMs are key components mediating immune responses within the tumor microenvironment (TME). Considering their refractory properties, simultaneous remodeling of TAMs and TIDCs is a potential strategy of boosting tumor immunity and restoring immunosurveillance. In this study, mannose-decorated poly(lactic- co -glycolic acid) nanoparticles loading with R848 (Man-pD-PLGA-NP@R848) were prepared to dually target TAMs and TIDCs for efficient tumor immunotherapy. The three-dimensional (3D) cell culture model can simulate tumor growth as influenced by the TME and its 3D structural arrangement. Consequently, cancer spheroids enriched with tumor-associated macrophages (TAMs) were fabricated to assess the therapeutic effectiveness of Man-pD-PLGA-NP@R848. In the TME, Man-pD-PLGA-NP@R848 targeted both TAMs and TIDCs in a mannose receptor-mediated manner. Subsequently, Man-pD-PLGA-NP@R848 released R848 to activate Toll-like receptors 7 and 8, following dual-reprograming of TIDCs and TAMs. Man-pD-PLGA-NP@R848 could uniquely reprogram TAMs into antitumoral phenotypes, decrease angiogenesis, reprogram the immunosuppressive TME from "cold tumor" into "hot tumor", with high CD4+ and CD8+ T cell infiltration, and consequently hinder tumor development in B16F10 tumor-bearing mice. Therefore, dual-reprograming of TIDCs and TAMs with the Man-pD-PLGA-NP@R848 is a promising cancer immunotherapy strategy. [Display omitted] • 3D spheroid (+TAM) models mimic the tumor models in clinical cancer patients. • The more M2-TAMs are in TME, the more macrophages are polarized to M1 phenotype. • Man-pD-PLGA-NP@R848 activates CD4+ and CD8+ T lymphocytes in TILs. • Man-pD-PLGA-NP@R848 stimulates and enhances the tumor-infiltrated cytokines level. • Man-pD-PLGA-NP@R848 as intratumoral immunotherapy to modulate tumor into hot state. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF